| Literature DB >> 20525188 |
Alexandra Schneider1, Lucas M Neas, Don W Graff, Margaret C Herbst, Wayne E Cascio, Mike T Schmitt, John B Buse, Annette Peters, Robert B Devlin.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2010 PMID: 20525188 PMCID: PMC2896918 DOI: 10.1186/1743-8977-7-14
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Hematological measurements.
| Acute-phase reaction | C-reactive protein (CRP), albumin, fibrinogen |
| Pro-inflammatory cytokines | Interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) |
| Endothelial dysfunction | Soluble intercellular adhesion molecules-1 (sICAM-1), soluble vascular cell adhesion molecules-1 (sVCAM-1), soluble endothelial-leukocyte adhesion molecule (E-selectin) |
| Platelet activation | Von Willebrand factor (vWf) |
| Coagulation pathway | Factor VII, factor IX, protein C, fibrinogen |
| Fibrinolysis pathway | Plasminogen, D-dimer, tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1) |
| Blood lipids | Total cholesterol (TC), triglycerides, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL) |
| Red blood cells count (RBC) | Mean corpuscular volume (MCV) |
| White blood cells count (WBC) | Monocytes, neutrophils, eosinophils, lymphocytes |
| Platelets | |
| Total hemoglobin | |
| Mean corpuscular hemoglobin (MCH) | |
Electrocardiogram and blood pressure parameters.
| RMSSD | Root mean square of successive differences |
| SDNN | Standard deviation of NN (normal-to-normal) |
| pNN50 | Percentage of adjacent NN-intervals which differ more than 50 ms |
| HR | Heart rate |
| TP | Total power (approximately = 0.40 Hz) |
| LFa | Low frequency band (0.04-0.15 Hz) |
| HFa | High frequency band (0.15-0.40 Hz) |
| LF/HF | Low-to-high frequency power ratio |
| QTc | Bazett-corrected QT interval (correction: QT/sqrt(NN)) |
| QT norm | Normalized QT variance |
| QTVI | QT variability index |
| T wave amplitude | Amplitude of T wave |
| T wave complexity | Principal component analysis of T wave |
| Variability of T wave complexity | Standard deviation of T wave complexity |
| BPsys | Systolic blood pressure |
| BPdia | Diastolic blood pressure |
aRepresented as absolute values of power (unit: ms2) and as the relative value of each power component in proportion to total power minus the very low frequency component (unit: normalized units)
Potential selected effect modifiers.
| Body mass index (BMI) | Cutpoint 30 kg/m2 |
| Age | Cutpoint 60 years |
| Glycosylated hemoglobin A1c (HbA1c) | Cutpoint 7% |
| Adiponectin-level in blood | Cutpoint 3700 ng/ml |
| Myeloperoxidase (MPO)-level in blood | Cutpoint 7 ng/ml |
| Ferritin-level in blood | Cutpoint 60 ng/ml |
| Glutathione S-transferase M1 ( | Yes/No |
| Beta-adrenergic receptor (BB) | Yes/No |
| Statins | Yes/No |
| Aspirin | Yes/No |
Description of the study population characteristics: current non-smoking subjects with type 2 diabetes mellitus.
| Individual Characteristics | N = 22 individuals |
|---|---|
| Mean (± SD) or total number N (%) | |
| Age [yrs] | 61 (± 8) |
| Age ≥ 60 yrs | 13 (59) |
| Gender: male | 14 (64) |
| Ethnicity: | |
| Caucasian | 15 (68) |
| African-American | 6 (27) |
| Hispanic-American | 1 (5) |
| Body mass index (BMI) [kg/m2] | 33 (± 7) |
| Body mass index (BMI) ≥ 30 kg/m2 | 12 (55) |
| Average systolic blood pressure ≥ 140 mmHg | 9 (41) |
| Smoking-status | |
| Never-smoker | 12 (55) |
| Ex-smoker | 10 (45) |
| Null polymorphism of | 10 (45)b |
aGSTM1: Glutathione S-transferase M1
bFour subjects declined permission for genetic testing.
Description of the study population clinical characteristics: current non-smoking subjects with type 2 diabetes mellitus.
| Clinical Characteristics | N = 22 individuals |
|---|---|
| Total number N (%) or mean (± SD) | |
| Type 2 diabetes mellitus | 22 (100) |
| Time since diabetes diagnosis [yrs] | 6.4 (± 5.0) |
| Hyperlipidemia | 19 (86) |
| Hypertension | 19 (86) |
| Past myocardial infarction | 0 (0) |
| Coronary artery disease | 4 (18) |
| Peripheral vascular disease | 3 (14) |
| Cerebrovascular disease | 1 (5) |
| Diabetic retinopathy | 1 (5) |
| Diabetic nephropathya | 8 (36) |
| Total number N (%) | |
| Glycosylated hemoglobin A1c (HbA1c) ≥ 7%b | 9 (41)c |
| Myeloperoxidase (MPO) ≥ 7 ng/mlb | 41 (51)d |
| Ferritin ≥ 60 ng/mlb | 36 (41)e |
| Adiponectin < 3700 ng/mlb | 11 (50)f |
| Homocysteine ≥ 12 μmol/lb | 11 (50)c |
| Total number N (%) | |
| Sulfonylureas | 10 (45) |
| Thiazolidinediones | 6 (27) |
| Metformin | 14 (64) |
| Statins | 12 (55) |
| Aspirin | 14 (64) |
| Beta-adrenergic receptor blockers (BB) | 9 (41) |
| Angiotensin converting enzyme-inhibitors | 12 (55) |
| Calcium-blockers | 2 (9) |
| Diuretics | 8 (36) |
| Angiotension II-receptor blocker | 3 (14) |
| Estrogen | 2 (9) |
aBased on the screening urine (>30 μg albumin/mg creatinine) on spot collection
bGlycosylated hemoglobin A1c was only measured once, myeloperoxidase, adiponectin and homocysteine were measured on all four visits. For the interaction analysis with myeloperoxidase all observations per patient were used as it showed high daily variation within individuals. For ferritin all observations per patient were used as there were some single missing observations - however, there was only low daily variation within individuals. For the interaction analysis with adiponectin the mean of the four measurements per individual was used. For homocyteine the mean of the four measurements per individual was calculated.
cData was missing from two subjects.
dData was missing for 8 observations.
eData was missing for 14 observations.
fData was missing from one subject.
Figure 1Effect estimates for soluble blood-data with 95%-confidence intervals for immediate and delayed associations with PM.
Figure 2Effect estimates for blood panel-data with 95%-confidence intervals for immediate and delayed associations with PM.
Figure 3Effect estimates for ECG-data with 95%-confidence intervals for immediate and delayed associations with PM. All estimates are shown for individuals without beta-blocker intake. For T wave amplitude one individual was excluded due to very strong associations at lag 0. For 24 hour-ECGs lag 0 means the association between the 24 hour air pollution average concurrent to the ECG measurement.
Figure 4Effect modification estimates for interleukin-6 with 95%-confidence intervals for immediate and delayed associations with PM. P-values for the significance of the interaction term are given if p ≤ 0.10.
Figure 5Effect modification estimates for red blood cell count with 95%-confidence intervals for immediate and delayed associations with PM. P-values for the significance of the interaction term are given if p ≤ 0.10.
Figure 6Timing of health effects in association with ambient PM.